TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GALAPAGOS

TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GALAPAGOS Share Price

DE000SV8WD20

Market Closed - Deutsche Boerse AG 01:13:13 01/06/2024 am IST
10.08 ^EUR	+6.22%

1 month	-8.28%
3 months	-41.73%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GALAPAGOS NV

Chart TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GALAPAGOS

Latest news about GALAPAGOS NV

Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment	31/05	MT
Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug	31/05	MT
Galapagos : Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T cell therapy candidate, uza cel, in head & neck cancer and potential future so	31/05	PU
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications	31/05	GL

More news

Quotes 5-day view

Date	Price	Change
31/24/31	10.08	+6.22%
30/24/30	9.49	+2.71%
29/24/29	9.24	-2.12%
28/24/28	9.44	-2.38%
27/24/27	9.67	+1.90%

Delayed Quote Deutsche Boerse AG

Last update May 01, 2024 at 01:13 am IST

More quotes

Static data

Product type	Knock-Out without Stop Loss
Buy / Sell	CALL
Underlying	GALAPAGOS NV
Issuer	Société Générale
WKN	SV8WD2
ISIN	DE000SV8WD20
Date issued	04/07/2023
Strike	16.08 €
Maturity	Unlimited
Parity	1 : 1
Emission price	23.65 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	25.71 €
Lowest since issue	9.12 €

Company Profile

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.

Sector

More about the company

Ratings for Galapagos NV

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Galapagos NV

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

25.74 EUR

Average target price

37.03 EUR

Spread / Average Target

+43.86%

Consensus